|
|
|
| home > white papers > Choosing the Right CMO for HPAPI Manufacturing - AMRI |
|
|
 WHITE PAPERS |
|
AMRI
|
|
Choosing the Right CMO for HPAPI Manufacturing
|
|
Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Significant improvement in overall survival with ERLEADA®▼ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer
BEERSE, BELGIUM, May 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA®▼ (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.1 Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Programme (Abstract #5516) beginning on Friday 29th May.
More info >> |
|
 |
White Papers |
 |
|
 |
Industry Events |
 |
Outsourcing in Clinical Trials Europe
26-27 October 2020, Paris, France
Arena International are delighted to announce the return of Outsourcing
in Clinical Trials Europe. Part of our global series of events, this
flagship show will attract the leading clinical professionals from
across Europe. The 10th Annual event will be hosted in Paris.
More info >> |
|
|
|
